FDA Inspection 1215034 — Granules Pharmaceuticals Inc.

Granules Pharmaceuticals Inc. — FEI 3011585184

The FDA completed an inspection of Granules Pharmaceuticals Inc. on August 3, 2023 in Chantilly, VA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
August 3, 2023
Fiscal Year
2023
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Chantilly, VA (United States)

Additional Details

Postmarket Adverse Drug Experience (PADE)